tbuckley/cabot-search huggingface dataset:
Electrocardiography Evolution in a Woman Presenting With Alcohol Withdrawal Seizures and Cocaine Use
Authors: Jonathan Chou, Lisa R. Beutler, Nora Goldschlager
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
PROGNOSTIC VALUE OF RIGHT ATRIAL 2-DIMENSIONAL SPECKLE TRACKING ECHOCARDIOGRAPHY IN CLINICAL AND HEMODYNAMIC EVALUATION OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TREATED WITH SPECIFIC THERAPY
Authors: Ailia Giubertoni, Lorena Ferrarotti, Cristina Piccinino, Jacopo Zanaboni, Daniele Sola, Paolo Marino
Journal: Journal of the American College of Cardiology (2016)
FRI0339 Prevelance of MEFV gene mutations in chidren with juvenil idiopathic arthritis
Authors: E. Comak, M. Koyun, T. Bilgen, C.S. Dogan, A. Uslu Gokceoglu, S. Akman
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Mutations of the MEFV gene, which encodes pyrin protein, a negative regulator of inflammation, leads to Familial Mediterranean Fever (FMF). Recent studies with adults suggest that MEFV gene mutations may have a risk factor for other rheumatic diseases. <h3>Objectives</h3> In this study, we aimed to study the frequency of MEFV gene mutations in children with Juvenile Idiopathic Arthritis (JIA). <h3>Methods</h3> Children with JIA who had no typical symptoms of familial Mediterranean fever (FMF) were screened for the mutations in exon 2 and exon 10 of the <i>MEFV</i> gene. Each sample was screened for the mutations located in exon 2 and exon 10 of the <i>MEFV</i> gene by direct sequencing. <h3>Results</h3> A total of 52 children, 29 girls (55.8%), with a mean age of 9.6±4.4 years (2-16.6 years) were included. Patients were classified according to JIA subgroups as oligoarthritisin 26 (50%), polyarthritisin 13 (24.8%), systemic arthritis in11 (21.2%) patients and arthritis related with enthesitis and with inflammatory bowel disease one each. Eleven patients (21.2%) were heterozygous, two (3.8%) were homozygous and another two were compound heterozygous for MEFV gene. The allele frequency of MEFV mutations was found to be 18.2%, which is higher than the general population. No significant difference was found between the subgroups of JIA. <h3>Conclusions</h3> These finding suggest that mutations of the MEFV gene may present with varied distinct clinical presentations other than FMF. The MEFV gene may be responsible for diseases other than FMF. <h3>Disclosure of Interest</h3> None Declared
UTILIZATION OF MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION IN HEMODYNAMICALLY STABLE PATIENTS PRESENTING WITH ST ELEVATION MYOCARDIAL INFARCTION
Authors: Sopan Lahewala, Shilpkumar Arora, Sidakpal Panaich, Nilay Patel, Chirag Savani, Abhishek Deshmukh, Apurva Badheka
Journal: Journal of the American College of Cardiology (2016)
Abstract 2751: Fanconi anemia pathway and DNA repair-based prognostic signatures in ovarian cancer
Authors: Josephine Kang, Alan D'Andrea, David Kozono
Journal: Cancer Research (2011)

Abstract Introduction: Of the 21,000 patients diagnosed annually in the United States with epithelial ovarian cancer, approximately 75% present with Stage III-IV disease. The vast majority of these patients are treated with cytotoxic chemotherapy regimens, where clinical response may be associated with activity of DNA repair pathways in tumors. Characterizing these repair pathways should help predict clinical response to specific chemotherapeutic agents. Methods: We devised a set of 150 DNA repair genes with documented functional importance in key DNA repair pathways including base excision repair (BER), Fanconi Anemia (FA), homologous recombination (HR), mismatch repair (MMR), non-homologous end joining (NHEJ), nucleotide excision repair (NER) and translesion synthesis (TLS). We extracted microarray expression data for these genes for 511 tumors and 8 normal specimens using data from Agilent Custom 244K Gene Expression and Affymetrix Human Genome U133A arrays. We performed Significance Analysis of Microarrays (SAM) to determine which of the 150 DNA repair genes were significantly more expressed in tumor vs. normal specimens. We then generated Kaplan-Meier survival curves using overall survival data. Results: Using the Affymetrix data, we identified 57 genes that were significantly up-regulated with a median fold change of 3.15 (range, 2.03-6.07) and 6 genes that were significantly down-regulated with a median fold change of 2.67 (range, 2.11-4.74) among tumor vs. normal tissue samples by SAM (delta 1.013, false discovery rate 0%). SAM using the Agilent data showed similar results; a total of 46 genes were significant hits in both datasets. A DNA repair signature consisting of genes significant in both platforms was defined and revealed a correlation between high expression values and decreased survival (median overall survival 4.5 vs. 5.2 years, log-rank p = 0.0086). DNA repair signatures specific to individual repair pathways were defined and demonstrated that high FA pathway (BRCA2, FAAP24, FANCA, FANCE, FANCG, FANCI and PALB2) expression in particular was inversely correlated with survival (median overall survival 4.1 vs. 5.2 years, log-rank p = 0.029 and 0.019 for the Affymetrix and Agilent datasets, respectively). Conclusion: Evidence from literature supports the critical role of the Fanconi Anemia (FA) pathway in repairing DNA damage caused by platinum-based agents such as cisplatin and carboplatin, commonly utilized to treat ovarian cancer patients. We show that a DNA repair signature specific to FA can be utilized to identify patients with high FA expression, whom we hypothesize may be more resistant to traditional platinum-based therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2751. doi:10.1158/1538-7445.AM2011-2751
Abstract PD09-03: Disease Outcomes in Primary Breast Cancer Are Associated with Obesity, Lymph Node Status and Angiolymphatic Invasion
Authors: L Vona-Davis, JM Turner, V Gadiyaram, G Hobbs, B. Ducatman
Journal: Cancer Research (2010)

Abstract Background: Obesity is associated with higher rates of breast cancer and poorer survival. Our previous work has shown that lymph node metastases are more frequently associated with advanced disease in obese patients. We sought to investigate the association of obesity with angiolymphatic invasion on disease outcomes in patients with invasive breast cancer. Methods: This retrospective study involved 627 predominately white women with invasive breast cancer. Hospital tumor registry, charts, and pathology records provided demographics and tumor biologic features. Body mass index (BMI) values were categorized according to WHO criteria: normal or underweight (lean), &amp;lt; 25.0 kg/m2; overweight, 25.0 to 29.9 kg/m2; obese, 30.0 kg/m2 or higher. Univariate and multivariate analyses were conducted between BMI and clinical outcomes, controlling for menopausal status. Recurrence-free survival and overall survival were calculated and a log-rank test was used to determine significance between groups. Results: In our study cohort, 175 (27.9%) were normal weight, 211 (33.7%) overweight and 241 (38.4%) were considered obese. Greater lymph node involvement and angiolymphatic invasion (P = 0.04) were present with obesity. Triple-negative tumors were more common in those patients classified as overweight and obese (43%) compared to normal weight individuals (20%). Factors associated with BMI were tumor size and lymph node status. In postmenopausal women, obesity was associated with an increased risk of lymph node metastases (OR 1.81, 95% CI 1.14-2.91; P = 0.010) and angiolymphatic invasion (OR 2.09, 95% CI 1.01-4.72; P = 0.049) when compared with normal weight individuals. The probability of developing a relapse within 10 years was higher among women with BMI ≥30.0 with positive lymph nodes and the presence of angiolymphatic invasion. Conclusions: In obese women with breast cancers, higher rates of lymph node involvement and angiolymphatic invasion may explain poorer outcomes. These findings further support the relationship between obesity and the factors that are elaborated by adipocytes as instrumental in promoting a more aggressive growth and progression of breast cancer. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD09-03.
REPORT ON THERAPEUTIC PROPERTIES OF PENICILLIN: I. A Penicillin Therapeutic Research Unit
Authors: J. N. Barron, R. V. Christie, D. B. Fraser, L. P. Garrod, O. T. Mansfield, H. V. Morgan, R. Mowlem, I. M. Robertson, A. C. Roxburgh, I. A. Roxburgh, R. V. Christie, L. P. Garrod
Journal: BMJ (1944)
Increased Duration of Paid Maternity Leave Lowers Infant Mortality in Low- and Middle-Income Countries: A Quasi-Experimental Study
Authors: Arijit Nandi, Mohammad Hajizadeh, Sam Harper, Alissa Koski, Erin C. Strumpf, Jody Heymann
Journal: PLoS Medicine (2016)

Maternity leave reduces neonatal and infant mortality rates in high-income countries. However, the impact of maternity leave on infant health has not been rigorously evaluated in low- and middle-income countries (LMICs). In this study, we utilized a difference-in-differences approach to evaluate whether paid maternity leave policies affect infant mortality in LMICs.We used birth history data collected via the Demographic and Health Surveys to assemble a panel of approximately 300,000 live births in 20 countries from 2000 to 2008; these observational data were merged with longitudinal information on the duration of paid maternity leave provided by each country. We estimated the effect of an increase in maternity leave in the prior year on the probability of infant (<1 y), neonatal (<28 d), and post-neonatal (between 28 d and 1 y after birth) mortality. Fixed effects for country and year were included to control for, respectively, unobserved time-invariant confounders that varied across countries and temporal trends in mortality that were shared across countries. Average rates of infant, neonatal, and post-neonatal mortality over the study period were 55.2, 30.7, and 23.0 per 1,000 live births, respectively. Each additional month of paid maternity was associated with 7.9 fewer infant deaths per 1,000 live births (95% CI 3.7, 12.0), reflecting a 13% relative reduction. Reductions in infant mortality associated with increases in the duration of paid maternity leave were concentrated in the post-neonatal period. Estimates were robust to adjustment for individual, household, and country-level characteristics, although there may be residual confounding by unmeasured time-varying confounders, such as coincident policy changes.More generous paid maternity leave policies represent a potential instrument for facilitating early-life interventions and reducing infant mortality in LMICs and warrant further discussion in the post-2015 sustainable development agenda. From a policy planning perspective, further work is needed to elucidate the mechanisms that explain the benefits of paid maternity leave for infant mortality.
THU0240 The Comparative Effectiveness of Oral Methotrexate Versus Subcutaneous Methotrexate for the Initial Treatment of Early Rheumatoid Arthritis
Authors: G. Hazlewood, C. Thorne, J. Pope, G. Boire, B. Haraoui, C. Hitchon, E. Keystone, D. Tin, V. Bykerk
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Methotrexate (MTX) is considered the preferred initial DMARD for the treatment of rheumatoid arthritis, but the preferred route of administration (oral or subcutaneous) is unclear. <h3>Objectives</h3> To determine the comparative effectiveness of initial therapy with subcutaneous (sc) versus oral methotrexate (MTX) for patients with early rheumatoid arthritis (ERA) in routine clinical care. <h3>Methods</h3> Patients with early inflammatory arthritis initiating methotrexate therapy were included from the Canadian Early Arthritis Cohort (CATCH), a multicenter, prospective cohort study of patients with ERA. All patients had a diagnosis of RA by 2010 criteria, symptom duration &lt; 1 year and were MTX-naive or minimally exposed to MTX. The exposure was initial route of MTX (oral vs. sc) and the outcome was DAS-28 over the first year (3, 6, 9, 12 months). A linear generalized estimating equation (GEE) model was used to account for repeated measures within patients while adjusting for potential confounders. <h3>Results</h3> 653 patients were included (442 oral MTX, 211 sc MTX). Patients treated with sc MTX were more likely to have erosions at baseline (35% vs. 25%, p=0.01), were less likely to receive other DMARDs (38% vs. 58%, p&lt;0.01), and had a higher median starting dose of MTX (25 mg vs. 15 mg, p&lt;0.01). Other characteristics were similar between groups. In the GEE model, after adjusting for all potential confounders except starting dose of MTX, sc MTX was associated with a reduction in the average DAS-28 score over the first year of 0.23 [(95%CI:0.07, 0.39), p&lt;0.01]. After adjusting for starting dose, the route of MTX (oral/sc) was no longer significant (p=0.26), but for each additional mg of MTX, the average DAS-28 decreased by 0.02 [(95%CI:0.003, 0.04), p=0.02]. There was significant variability in the use of sc between centers. <h3>Conclusions</h3> Initial sc MTX use was associated with lower DAS28 scores over the first year of treatment, which appears to be mediated through the higher starting dose used in clinical practice. <h3>Acknowledgements</h3> Dr. Glen Hazlewood is supported by an Alberta Innovates Health Solutions Clinical Fellowship <h3>Disclosure of Interest</h3> G. Hazlewood: None Declared, C. Thorne: None Declared, J. Pope: None Declared, G. Boire: None Declared, B. Haraoui: None Declared, C. Hitchon: None Declared, E. Keystone: None Declared, D. Tin: None Declared, V. Bykerk Grant/research support from: Amgen, Pfizer, Roche, BMS, UCB, Janssen Biotech and Abbott
Transarterial Chemoembolisation Using Drug-Eluting Microspheres Dem-Tace in Lung Carcinoma Metastases to the Liver in Humans
Authors: B.U. Rybacka-Chabros, K. Pyra, T. Jargiełło, M. Szczerbo Trojanowska, P.Z. Chabros, J. Milanowski
Journal: Annals of Oncology (2015)
Abstract 3148: Immunohistochemical analysis of HB-EGF expression in breast, colon, gastric, hepatocellular, lung, ovarian, pancreatic and prostate cancer
Authors: Abdel-baset Halim, Lisa M. Dauffenbach, Christopher A. Kerfoot, William R. Stull, Esther Zwick-Wallasch, Richard Scheyer, Giorgio Senaldi
Journal: Cancer Research (2011)

Abstract Heparin-binding EGF-like growth factor (HB-EGF) is a member of the epidermal growth factor (EGF) family of proteins. It is synthesized as a transmembrane protein, which can be cleaved at the cell surface to release the soluble ectodomain sHB-EGF. HB-EGF has been implicated in several physiological and pathological processes, including tumorigenesis and metastasis. Anti-HB-EGF therapeutic monoclonal antibodies are currently under investigation and hold promise for treating multiple types of cancer. In order to investigate the relationship between HB-EGF expression in cancer and response to therapy, an immunohistochemical assay to HB-EGF was developed and validated. Antigen retrieval and antibody titration studies were performed for six antibodies in order to select an antibody with proper performance characteristics. The antibodies were tested in characterized xenografts, characterized cell lines, placenta (HB-EGF-positive) and/or ovarian cancer. Of the antibodies tested, the AF-259-NA goat polyclonal antibody demonstrated the appropriate staining pattern in xenografts, cell lines and placenta. The optimized immunohistochemistry assay was used to stain cancer samples, and the frequency of moderate (2+) or strong (3+) staining in cancer cells was as follows: gastric = 50%, hepatocellular = 50%, lung = 40%; ovarian = 38%, colon = 37%, breast-ER+ = 20%, bladder = 10%; breast-HER2+ = 10%, pancreatic = 10%, breast-triple negative = 0%, prostate = 0%. When compared by average H-score, the cancer ranked in the following order (H-score in parenthesis): Hepatocellular (69), ovarian (37), gastric (23), breast-HER2+ (14), breast-ER+ (12), pancreatic (10), lung (5), breast-triple negative (2), colon (2), bladder (1), prostate (1). For comparison, H-scores for normal tissues were as follows: Normal bladder epithelium (74), stomach (24), colon (8), prostate (3), ovary (1), liver (1), breast (0), lung (0) and epidermis (0). In summary, immunohistochemistry using the AF-259-NA antibody produces the expected staining pattern in characterized samples and can be applied to human cancer samples to evaluate the relationship between clinical response and HB-EGF expression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3148. doi:10.1158/1538-7445.AM2011-3148
Comparison of Radionuclide Imaging and Ultrasonography in the Differentiation of Acute Testicular Torsion and Inflammatory Testicular Disease
Authors: HSI-CHIN WU, SHUNG-SHUNG SUN, ALBERT KAO, FENG-JU CHUANG, CHENG-CHIEH LIN, CHENG-CHUN LEE
Journal: Clinical Nuclear Medicine (2002)

Purpose Torsion of the testis is a urologic emergency that requires early diagnosis and prompt surgical treatment for testicular survival. However, the early differential diagnosis of acute testicular torsion from epididymitis or orchitis is often difficult. The aim of this retrospective study was to evaluate and compare the value of Tc-99m pertechnetate radionuclide imaging and ultrasonography in the differentiation of acute testicular torsion and inflammatory testicular diseases. Methods Twenty patients (age range, 5 to 38 years) with possible acute testicular torsion from July 2000 to July 2001 were enrolled in this study. Ultrasonography was performed in all patients in the emergency room. Within 3 hours of ultrasonography, radionuclide imaging was also performed after intravenous injection of 5 to 15 mCi Tc-99m pertechnetate in the forearms. All of the patients with clinically suspected acute testicular torsion underwent surgery. The surgical findings and pathologic reports of these patients were reviewed and definite diagnoses were established. None of the other patients had surgery and were followed clinically for at least 1 month after ultrasonography and radionuclide imaging. Results Four patients with testicular torsion, 13 patients with inflammatory testicular disease, and three healthy persons had a final surgical and pathologic diagnosis or clinical follow-up, and all were accurately diagnosed by Tc-99m pertechnetate radionuclide imaging. In contrast, ultrasonography was less accurate in the diagnosis and differentiation of acute testicular torsion from inflammation. Only 1 of 4 patients with testicular torsion, 5 of 13 patients with inflammatory testicular disease, and 2 of 3 healthy persons were diagnosed by ultrasonography. Conclusions The results indicate that Tc-99m pertechnetate radionuclide imaging is a more useful and accurate imaging method than ultrasonography in the detection and differentiation of acute testicular torsion from inflammatory testicular disease in patients with acute scrotal pain.
<i>TWIST1</i> and <i>PITX2</i> expression in bone marrow of women with clinical stage II/III breast cancer identifies patients at risk for the development of early metastatic disease.
Authors: N Dasgupta, M Watson, T Fleming, K Trinkaus, A Ferguson, R Aft
Journal: Cancer Research (2009)

Abstract Abstract #108 Background: The presence of disseminated tumor cells (DTCs) in bone marrow of women with newly diagnosed breast cancer has been associated with increased risk of recurrent disease development. We have previously described a 67-gene signature associated with the presence of DTCs using gene array analysis after immunomagnetic enrichment of these cells and found that the expression of one of the 67-genes in bone marrow of breast cancer patients, TWIST1, correlated with the development of early recurrent disease. We have now tested the remaining genes in the 67-gene signature for correlation with the development of recurrent disease. Our goal is to identify genes associated with DTCs with high metastatic potential for early detection and intervention.&amp;#x2028; Methods: Expression of each of the 67 genes was analyzed using qRT-PCR in a breast cancer cell lines (MCF7, SKBR3, MDA/MB 231) diluted into normal human bone marrow at varying concentrations. Levels of expression in the breast cancer cells and in human bone marrow were quantitated. Genes with high expression in breast cancer cell lines and no observed expression in normal human bone marrow were further tested by qRT-PCR for expression in a validation set of bone marrows comprised of 50 specimens collected from 30 patients with clinical stage II/III breast cancer prior to any treatment. Thirteen of these patients developed recurrent disease within 16 months.&amp;#x2028; Results: Within the 67 gene signature, 5 genes were identified that were highly expressed in breast cancer cell lines and had no detectable expression in normal human bone marrow. Expression of the 5 genes as well as keratin 19 were examined in the validation set of bone marrows. PITX2 was expressed in the bone marrow of 5 of the 13 patients who recurred within one year. Only expression of TWIST1 and PITX2 were found to correlate with the time to development of early recurrent disease (p &amp;lt;0.0001 and 0.0002 respectively).&amp;#x2028; Conclusion: We have found that the expression of TWIST1 and PITX2 in the bone marrow of breast cancer patients prior to any treatment identifies patients at risk of early distant disease recurrence. These genes are not expressed in normal human bone marrow. Both are transcription factors involved in the embryonic development and appear to be expressed by DTCs with high metastatic potential. Expression of TWIST1 and PITX2 may prove to be excellent markers for identifying women at high risk for distant relapse and lead to new targets for chemotherapeutic intervention. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 108.
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Authors: Seema Singhal, Jayesh Mehta, Raman Desikan, Dan Ayers, Paula Roberson, Paul Eddlemon, Nikhil Munshi, Elias Anaissie, Carla Wilson, Madhav Dhodapkar, Jerome Zeldis, David Siegel, John Crowley, Bart Barlogie
Journal: New England Journal of Medicine (1999)

Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease.